Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intel: Emerging Markets Are Fertile Frontier For CRM Device-Makers

Executive Summary

The global cardiac rhythm management market is set to grow at a compound annual growth rate of 4.8% to about $13.5bn by 2021. This article, based on findings from a Meddevicetracker report, provides an in-depth look at where the growth markets are, the evolving competitive landscape, and discusses the key players and upcoming technological trends that will bolster this market.

You may also be interested in...



Abbott Finally Joins MRI-Compatibility Club In US CRM Market

The firm’s Assurity MRI pacemaker and Tendril MRI pacing lead, acquired in its recent St. Jude Medical deal, gained US FDA approval after some delay. Lack of this designation has been a competitive challenge for the business in the past year.

Abbott Becomes CRM Player Overnight By Completing St. Jude Deal

Abbott Laboratories has finalized its $25b takeover of St. Jude Medical, first announced in April, making Abbott a major player in almost every corner of the $30bn cardiovascular device market.

Boston Scientific gets early nod for next-gen S-ICD

The US FDA has approved Boston Scientific's next-generation Emblem S-ICD subcutaneous implantable defibrillator earlier than expected with plans to launch in the US by this fall. The firm has also CE marked the device in Europe.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT104332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel